Axoft raises $18.1M total — ultra-soft Fleuron BCI validated in 11 humans across three sites
Summary
Axoft has raised $18.1M in total funding — lean by BCI standards — while achieving first-in-human validation of Fleuron probes in 4 patients at The Panama Clinic (FINESSE study), expanding to 11 patients across 3 sites including Mass General Brigham, licensing Fleuron material to Stanford, and publishing a medRxiv preprint demonstrating 18-month stable recording in rodents and first-in-human results. A Series B to fund FINESSE-2 and eventual FDA IDE is anticipated in 2026.
Why it matters
Axoft's capital efficiency — $18.1M to first-in-human validation of a novel BCI material — is remarkable by industry standards. Most BCI companies have spent $50M+ before first human use. This lean execution demonstrates that material science-focused BCI development can be more capital efficient than device-focused approaches, and positions Axoft well for a Series B fundraise against a strong data backdrop.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial